[Extracorporeal treatment with L-asparaginase (author's transl)]
- PMID: 269743
- DOI: 10.1007/BF00999458
[Extracorporeal treatment with L-asparaginase (author's transl)]
Abstract
L-asparaginase therapy is often limited by allergy or toxicity and probably in some cases by antibody mediated inactivation of the enzyme. These problems can be avoided by extracorporeal application of l-asparaginase. As the enzyme is a stable tetramer with high molecular weight it cannot pass through the dialysis membrane in contrast to the amino acid l-asparagin which is destroyed. The resulting l-asparagin depletion of the plasma is sufficient for therapeutic success. Effective extracorporeal l-asparaginase therapy is demonstrated in two patients with ALL who were resistant to other chemotherapy and could not be treated intravenously because of allergy and toxicity.
Similar articles
-
[L-Asparaginase therapy in chemotherapy-resistant acute lymphocytic leukemias (author's transl)].Rinsho Ketsueki. 1979 Apr;20(4):355-63. Rinsho Ketsueki. 1979. PMID: 286816 Japanese. No abstract available.
-
[Immunization against L-asparaginase. Demonstration and characteristics of antibodies. Clinical value].Nouv Presse Med. 1973 Jun 9;2(23):1575-8. Nouv Presse Med. 1973. PMID: 4197351 French. No abstract available.
-
Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.Cancer. 1972 Aug;30(2):376-81. doi: 10.1002/1097-0142(197208)30:2<376::aid-cncr2820300212>3.0.co;2-4. Cancer. 1972. PMID: 4559405 No abstract available.
-
[Recent advances in L-asparaginase studies].Gan To Kagaku Ryoho. 1988 May;15(5):1815-25. Gan To Kagaku Ryoho. 1988. PMID: 3285797 Review. Japanese.
-
[L-asparaginase and leukemia].Klin Wochenschr. 1969 Jan 15;47(2):61-4. doi: 10.1007/BF01745766. Klin Wochenschr. 1969. PMID: 4904781 Review. German. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials